Cargando…

Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report

BACKGROUND: Rituximab is a well-established component of treatment regimens for B-cell non-Hodgkin lymphoma. Rituximab binds the CD20 antigen on the surface of B lymphocytes, causing an enhanced clearance of malignant and benign B cells. Thus, rituximab leads to depletion of normal B lymphocytes as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Higer, Maximilian, Cana, Denis, Podlech, Juergen, Schadmand-Fischer, Simin, Schwarting, Andreas, Teschner, Daniel, Theobald, Matthias, Wölfel, Thomas, Hess, Georg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456041/ https://www.ncbi.nlm.nih.gov/pubmed/32859260 http://dx.doi.org/10.1186/s13256-020-02457-y

Ejemplares similares

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY
por: Tivey, A., et al.
Publicado: (2022)

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
por: Sun, Kai, et al.
Publicado: (2018)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
por: Novak, Urban, et al.
Publicado: (2023)

Bortezomib/ibrutinib/rituximab: Various toxicities: case report
Publicado: (2021)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
por: Galinier, Aliénor, et al.
Publicado: (2017)

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2017)

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2021)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY
por: Shotton, Rohan, et al.
Publicado: (2023)

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Giné, Eva, et al.
Publicado: (2022)

Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
por: Lamar, Zanetta, et al.
Publicado: (2015)

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: McNally, Gretchen Anne, et al.
Publicado: (2015)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
por: Fuhr, Viktoria, et al.
Publicado: (2022)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
por: Tucker, David L, et al.
Publicado: (2015)

Ibrutinib Caused Mediastinal Emphysema and Pneumothorax in the Treatment of a Patient with Mantle Cell Lymphoma
por: Tsutsumi, Yutaka, et al.
Publicado: (2019)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
por: Li, Yangguang, et al.
Publicado: (2017)

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
por: Mohanty, Atish, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
por: Locke, Clifford B, et al.
Publicado: (2020)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2023)

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
por: Rudelius, Martina, et al.
Publicado: (2018)

Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse
por: Oh, Timothy S., et al.
Publicado: (2022)

USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1
por: Zhang, Ye, et al.
Publicado: (2023)

Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
por: Ito, Yuta, et al.
Publicado: (2018)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
por: Hess, Georg, et al.
Publicado: (2020)

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
por: Okamoto, Koh, et al.
Publicado: (2016)

Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib
por: Messina, Julia A., et al.
Publicado: (2017)

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
por: Martin, Peter, et al.
Publicado: (2023)

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
por: Fischer, Luca, et al.
Publicado: (2023)

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2019)

Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review
por: Mannina, Donato, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_inu7377jdm538p8l00dhcaqsqu